Taiho files for Japanese approval of TAC-202 (bilastine)

16 November 2015

Japan’s Taiho Pharmaceutical has submitted an application for approval of the manufacture and marketing of TAC-202 (bilastine), an oral anti-allergy drug, to the Japanese Ministry of Health, Labor and Welfare.

Taiho, a subsidiary of Otsuka Pharmaceutical (TYO: 4768), is seeking approval of TAC-202 for the indication of allergic rhinitis, urticaria, and itching resulting from skin diseases (eczema/dermatitis, prurigo and cutaneous pruritus).

TAC-202, is an innovative anti-histamine product, discovered by Spanish drugmaker Faes Farma and was first approved in European Union in 2010. Taiho has developed TAC-202 after signing a license agreement with Faes Farma in July 2012 for the development and marketing rights in Japan. The product has been successfully approved in over 90 countries and regions* and marketed by several partners under the license from Faes Farma for the treatment of allergic rhinitis and urticaria.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK